Mary Jenkins | Senior Manager of Investor Relations |
Doug Ingram | President & Chief Executive Officer |
Louise Rodino-Klapac | Executive Vice President, Chief Scientific Officer and Head of R&D |
Dallan Murray | Senior Vice President & Chief Customer Officer |
Ian Estepan | Executive Vice President & Chief Financial Officer |
Gilmore O'Neill | Chief Medical Officer & Executive Vice President |
Anupam Rama | JPMorgan |
Gena Wang | Barclays |
Judah Frommer | Credit Suisse |
Tazeen Ahmad | Bank of America |
Salveen Richter | Goldman Sachs |
Colin Bristow | UBS |
Ritu Baral | Cowen |
Max Skor | Morgan Stanley |
Debjit Chattopadhyay | Guggenheim |
Brian Skorney | Baird |
Hartaj Singh | Oppenheimer |
Tim Lugo | William Blair |
Gil Blum | Needham |
Joseph Schwartz | SVB Securities |
Yun Zhong | BTIG |
Zhiqiang Shu | Bernberg |
Danielle Brill | Raymond James |
Kristen Kluska | Cantor Fitzgerald |
Gavin Clark-Gartner | Evercore |
Good day, ladies and gentlemen, thank you for standing by, and welcome to Sarepta Therapeutics Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' prepared remarks, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference may be recorded. I would now like to turn the conference over to your speaker host today, Mary Jenkins, Senior Manager of Investor Relations